Technical Analysis for BOLT - Bolt Biotherapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 1.14 | 2.70% | 0.03 |
BOLT closed up 2.7 percent on Monday, March 18, 2024, on 87 percent of normal volume. It ran into resistance at its 50 day moving average. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Mar 27
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
200 DMA Resistance | Bearish | 0.00% | |
50 DMA Resistance | Bearish | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
50 DMA Resistance | Bearish | 2.70% | |
Stochastic Reached Oversold | Weakness | 2.70% | |
Lower Bollinger Band Touch | Weakness | 2.70% | |
Oversold Stochastic | Weakness | 2.70% | |
200 DMA Resistance | Bearish | 3.64% | |
Fell Below 50 DMA | Bearish | 3.64% | |
Down 3 Days in a Row | Weakness | 3.64% |
Alert | Time |
---|---|
200 DMA Resistance | about 12 hours ago |
50 DMA Resistance | about 12 hours ago |
Rose Above Previous Day's High | about 12 hours ago |
Rose Above 200 DMA | about 12 hours ago |
Up 5% | about 12 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/27/2024
Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors. Its preclinical stage product candidates include carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. Bolt Biotherapeutics, Inc. was founded in 2015 and is based Redwood city, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Tumor Pharmaceutical Products Cancer Immunotherapy Breast Cancer Immune Checkpoint Her2/Neu
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Tumor Pharmaceutical Products Cancer Immunotherapy Breast Cancer Immune Checkpoint Her2/Neu
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 2.03 |
52 Week Low | 0.84 |
Average Volume | 115,662 |
200-Day Moving Average | 1.15 |
50-Day Moving Average | 1.15 |
20-Day Moving Average | 1.20 |
10-Day Moving Average | 1.21 |
Average True Range | 0.08 |
RSI (14) | 46.52 |
ADX | 21.88 |
+DI | 21.36 |
-DI | 20.97 |
Chandelier Exit (Long, 3 ATRs) | 1.15 |
Chandelier Exit (Short, 3 ATRs) | 1.32 |
Upper Bollinger Bands | 1.32 |
Lower Bollinger Band | 1.08 |
Percent B (%b) | 0.24 |
BandWidth | 19.80 |
MACD Line | 0.01 |
MACD Signal Line | 0.03 |
MACD Histogram | -0.0178 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.24 | ||||
Resistance 3 (R3) | 1.24 | 1.21 | 1.23 | ||
Resistance 2 (R2) | 1.21 | 1.18 | 1.21 | 1.22 | |
Resistance 1 (R1) | 1.17 | 1.16 | 1.19 | 1.17 | 1.22 |
Pivot Point | 1.14 | 1.14 | 1.15 | 1.14 | 1.14 |
Support 1 (S1) | 1.10 | 1.11 | 1.12 | 1.11 | 1.06 |
Support 2 (S2) | 1.07 | 1.09 | 1.07 | 1.06 | |
Support 3 (S3) | 1.03 | 1.07 | 1.05 | ||
Support 4 (S4) | 1.04 |